News and Trends 1 Nov 2022 Pancreatic cancer could be diagnosed years earlier Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research from the U.K. shows. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates. In the largest study of its kind, researchers […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Tetris Pharma launches hypoglycemia injector pen in Germany Tetris Pharma Ltd, a subsidiary of biopharma company Arecor Therapeutics plc, has launched Ogluo (glucagon prefilled autoinjector pen) in Germany as a treatment for severe hypoglycemia in children and adults living with diabetes. Ogluo is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycemia. […] November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Human Immunology Biosciences launches with $120M Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices. Few targeted therapies exist for the autoimmune, allergic […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Efflux pump inhibitor research may lead way to beating AMR Researchers from SANKEN (The Institute of Scientific and Industrial Research), at Osaka University in Japan have provided new insights into the relationship between the position of “bulky” amino acids on bacterial proteins and the ability of bacteria to resist antibiotics. The medical profession is losing a race. Bacterial antibiotic resistance doesn’t only threaten the ability […] October 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Replay Bio launches HSV gene therapy company to target retinal eye disease Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […] October 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Scientists say RNA production inhibitors important in cancer research A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, shows that inhibiting RNA synthesis after radiation therapy facilitates the death of tumor cells. The study was published in the journal Nature Communications. RNA has been shown to be essential for repairing […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Startup BioRaptor raises $3M to drive AI insights for scientists BioRaptor has raised $3M in funding, which it says will allow it to put the power of AI-generated insights into the hands of every scientist. The round was led by lool Ventures and CPT Capital and was joined by FoodHack and other strategic angel investors. BioRaptor is building an operating system for biology research and […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Reprogramming immune cells can fight melanoma A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard-to-treat skin cancer, melanoma. The University of Bristol, in the U.K. led the discovery, which has been published in Advanced Science. It demonstrates a new way to clear early stage pre-cancerous and even […] October 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022 Rila Therapeutics exits stealth mode to address renal fibrosis Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […] October 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022 AKT inhibitor shows signs of effectiveness in patient trial In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […] October 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […] October 28, 2022 Share WhatsApp Twitter Linkedin Email